«Especially with what's called
next generation sequencing or whole genome sequencing where it's not just one patent
holder you have to deal with there is a real fear Canadian hospitals and researchers will be locked out of this domain and it could hurt us in terms of delivery of the service, health - care costs, and being locked out of innovation — those were the three important things at
stake,» says Gold.